Enhancing screening adherence for strongyloides infection in latinx inpatients with COVID-19: a local protocol implementation study

References

• Page W, Judd JA, Bradbury RS. The unique life cycle of strongyloides stercoralis and implications for public health action trop med infect dis. Trop Med Infect Dis. 2018;3(2):53. doi: 10.3390/tropicalmed3020053
   PubMedGoogle Scholar
• Greaves D, Coggle S, Pollard C, et al. Strongyloides stercoralis infection. BMJ. 2013;347(3):f4610. doi: 10.1136/bmj.f4610
   PubMedGoogle Scholar
• Vasquez-Rios G, Pineda-Reyes R, Pineda-Reyes J, et al. Strongyloides stercoralis hyperinfection syndrome: a deeper understanding of a neglected disease. J Parasit Dis. 2019;43(2):167–175. doi: 10.1007/s12639-019-01090-x
   PubMedGoogle Scholar
• Ahn DG, Shin HJ, Kim MH, et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J Microbiol Biotechnol. 2020;30(3):313–324. doi: 10.4014/jmb.2003.03011
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. doi: 10.1001/jama.2020.1585
   PubMed Web of Science ®Google Scholar
• Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782–793. doi: 10.1001/jama.2020.12839
   PubMed Web of Science ®Google Scholar
• RECOVERY Collaborative GroupHorby P, Lim WS. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384(8):693–704. doi: 10.1056/NEJMoa2021436
   PubMed Web of Science ®Google Scholar
• Ramiro S, Mostard RLM, Magro-Checa C, et al. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study. Ann Rheum Dis. 2020;79(9):1143–1151. doi: 10.1136/annrheumdis-2020-218479
   PubMed Web of Science ®Google Scholar
• Marchese V, Crosato V, Gulletta M, et al. Strongyloides infection manifested during immunosuppressive therapy for SARS-CoV-2 pneumonia. Infection. 2020;10(3):539–542. doi: 10.1007/s15010-020-01522-4
   Google Scholar
• Lier AJ, Tuan JJ, Davis MW, et al. Case report: disseminated strongyloidiasis in a patient with COVID-19. Am J Trop Med Hyg. 2020;103(4):1590–1592. doi: 10.4269/ajtmh.20-0699
   PubMed Web of Science ®Google Scholar
• Pintos-Pascual I, López-Dosil M, Castillo-Núñez C, et al. Eosinophilia and abdominal pain after severe pneumonia due to COVID 19. Enferm Infec Microbiol Clin. 2020 10;39(9):478–480. doi: 10.1016/j.eimc.2020.10.014
   Web of Science ®Google Scholar
• Gann PH, Neva FA, Gam AA. A randomized trial of single- and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis. J Infect Dis. 1994;169(5):1076–1079. doi: 10.1093/infdis/169.5.1076
   PubMed Web of Science ®Google Scholar
• Buonfrate D, Salas-Coronas J, Muñoz J, et al. Multiple-dose versus single-dose ivermectin for strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial. Lancet Infect Dis. 2019;19(11):1181–1190. doi: 10.1016/S1473-3099(19)30289-0
   PubMed Web of Science ®Google Scholar
• Stauffer WM, Alpern JD, Walker PF. COVID-19 and dexamethasone: a potential strategy to avoid steroid-related strongyloides hyperinfection. JAMA. 2020;324(7):623–624. doi: 10.1001/jama.2020.13170
   PubMed Web of Science ®Google Scholar
• De Wilton A, Nabarro LE, Godbole GS, et al. Risk of strongyloides hyperinfection syndrome when prescribing dexamethasone in severe COVID-19. Travel Med Infect Dis. 2020;40:101981. doi: 10.1016/j.tmaid.2021.101981
   Web of Science ®Google Scholar
• McDermott CV, Alicic RZ, Harden N, et al. Put a lid on it: are fecal bio-aerosols a route of transmission for SARS-CoV-2? J Hosp Infect. 2020;105(3):397–398. doi: 10.1016/j.jhin.2020.04.024
   PubMed Web of Science ®Google Scholar
• Public health guidance on screening and vaccination for infectious diseases in newly arrived migrants within the EU/EEA. European Centre For Disease Prevention And Control. 2018. Available at https://www.ecdc.europa.eu/sites/default/files/documents/Public%20health%20guidance%20on%20screening%20and%20vaccination%20of%20migrants%20in%20the%20EU%20EEA.pdf. Last access: 4 June 2023.
   Google Scholar
• Krolewiecki A, Nutman TB. Strongyloidiasis: A neglected tropical disease. Infect Dis Clin North Am. 2019;33(1):135–151. doi: 10.1016/j.idc.2018.10.006
   PubMed Web of Science ®Google Scholar
• Requena-Méndez A, Buonfrate D, Gomez-Junyent J, et al. Evidence-based guidelines for screening and management of strongyloidiasis in non-endemic countries. Am J Trop Med Hyg. 2017;97(3):645–652. doi: 10.4269/ajtmh.16-0923
   PubMed Web of Science ®Google Scholar
• Rodrigo-Muñoz JM, Sastre B, Canas JA, et al. Eosinophil response against classical and emerging respiratory viruses: COVID-19. J Investig Allergol Clin Immunol. 2021;31(2):94–107. doi: 10.18176/jiaci.0624
   PubMed Web of Science ®Google Scholar
• Stylemans D, Van Cauwelaert S, D’Haenens A, et al. COVID-19–associated eosinopenia in a patient with chronic eosinophilia due to chronic strongyloidiasis. Infect Dis Clin Pract (Baltim Md). 2021;29(5):e305–e306. doi: 10.1097/IPC.0000000000000991
   PubMed Web of Science ®Google Scholar
• Lindsley AW, Schwartz JT, Rothenberg ME. Eosinophil responses during COVID-19 infection and coronavirus vaccination. J Allergy Clin Immunol. 2020;146(1):1–7. doi: 10.1016/j.jaci.2020.04.021
   PubMed Web of Science ®Google Scholar
• Malinis M, Boucher HW, AST. Screening of donor and candidate prior to solid organ transplantation—guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant. 2019;33(9):e13548. doi: 10.1111/ctr.13548
   PubMedGoogle Scholar
• Gómez Reino J, Loza E, Andreu JL, et al. Consensus statement of the Spanish society of Rheumatology on risk management of biologic therapy in rheumatic patients. Reumatol Clin. 2011;7(5):284–298. doi: 10.1016/j.reumae.2011.05.001
   PubMedGoogle Scholar
• Geri G, Rabbat A, Mayaux J, et al. Strongyloides stercoralis hyperinfection syndrome: a case series and a review of the literature. Infection. 2015;43(6):691–698. doi: 10.1007/s15010-015-0799-1
   PubMed Web of Science ®Google Scholar
• Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19 https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ (Accessed on December 6, 2022).
   Google Scholar
• Muhi S, Ko DK, McGuinness SL, et al. Mixed‐method analysis of screening for Strongyloides stercoralis prior to immunosuppression: a problem of limited bandwidth? Intern Med J. 2022;52(5):790–799. doi: 10.1111/imj.14991
   PubMed Web of Science ®Google Scholar
• Asundi A, Beliavsky A, Liu XJ, et al. Prevalence of strongyloidiasis and schistosomiasis among migrants. Lancet Glob Health. 2019;7(2):e236–e248. doi: 10.1016/S2214-109X(18)30490-X
   PubMed Web of Science ®Google Scholar
• Salvador F, Treviño B, Bosch-Nicolau P, et al. Strongyloidiasis screening in migrants living in Spain: systematic review and meta-analysis. Trop Med Int Health. 2020;25(3):281–290. doi: 10.1111/tmi.13352
   PubMed Web of Science ®Google Scholar
• Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787. doi: 10.1016/j.antiviral.2020.104787
   PubMed Web of Science ®Google Scholar
• Chaccour C, Hammann F, Ramón-García S, et al. Ivermectin and COVID-19: Keeping rigor in times of urgency. Am J Trop Med Hyg. 2020;102(6):1156–1157. doi: 10.4269/ajtmh.20-0271
   PubMed Web of Science ®Google Scholar
• Rodríguez-Guardado A, Álvarez-Martínez MJ, Flores MD, et al. Screening for strongyloidiasis in Spain in the context of the SARS-CoV-2 pandemic: Results of a survey on diagnosis and treatment. Enferm Infec Microbiol Clin. 2022;41(6):329–334. doi: 10.1016/j.eimce.2022.08.006. Engl Ed.
   Web of Science ®Google Scholar
• Wikman-Jorgensen PE, Llenas-Garcia J, Shedrawy J, et al. Cost-effectiveness of different strategies for screening and treatment of Strongyloides stercoralis in migrants from endemic countries to the European Union. BMJ Glob Health. 2020;5(5):e002321. doi: 10.1136/bmjgh-2020-002321
   PubMedGoogle Scholar